Media headlines about Five Prime Therapeutics (NASDAQ:FPRX) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5111829079551 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities analysts have commented on the stock. ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. BMO Capital Markets lifted their price objective on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Zacks Investment Research cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. BidaskClub raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $41.00 price objective on shares of Five Prime Therapeutics in a research note on Wednesday, October 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $64.00.

Five Prime Therapeutics (FPRX) opened at $20.54 on Wednesday. Five Prime Therapeutics has a 52 week low of $19.73 and a 52 week high of $49.30. The company has a market cap of $613.03, a PE ratio of -4.06 and a beta of 3.91.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The firm had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same period in the prior year, the firm posted ($0.72) earnings per share. Five Prime Therapeutics’s revenue for the quarter was up 24.7% on a year-over-year basis. analysts predict that Five Prime Therapeutics will post -5.56 EPS for the current year.

In related news, Director William R. Ringo sold 600 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total transaction of $27,198.00. Following the completion of the transaction, the director now directly owns 600 shares of the company’s stock, valued at approximately $27,198. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.50% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with's FREE daily email newsletter.